Are patients with lung cystic fibrosis at increased risk of severe and fatal COVID-19? Interleukin 6 as a predictor of COVID-19 outcomes.

Marcinkiewicz, Janusz; Mazurek, Henryk; Majka, Grzegorz; Chain, Benjamin

Marcinkiewicz, Janusz; Mazurek, Henryk; Majka, Grzegorz; Chain, Benjamin.

Afiliação

Marcinkiewicz J; Chair of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland. janusz.marcinkiewicz@uj.edu.pl
Mazurek H; Department of Pneumonology and Cystic Fibrosis, Institute of Tuberculosis and Lung Disorders, Rabka-Zdrój, Poland
Majka G; Chair of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
Chain B; Division of Infection and Immunity, University College London, London, United Kingdom

Pol Arch Intern Med ; 130(10): 919-920, 2020 10 29.

Article em En | MEDLINE | ID: mdl-33016684

Assuntos

Infecções por Coronavirus; Coronavirus; Fibrose Cística; Pandemias; Pneumonia Viral; Betacoronavirus; COVID-19; Humanos; Sistema Imunitário; Interleucina-6; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Coronavirus / Fibrose Cística / Pandemias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google